pcv2 Archives | Mhyosphere

PCV2 & Mycoplasma Hyponeumoniae: Piglet vaccination

12 Dec Circovirus in pigs: always a bull’s eye?

Posted at 10:30h in pcv2

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="80px"][/vc_column][vc_column][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][qode_elements_holder number_of_columns="one_column"][qode_elements_holder_item advanced_animations="no" item_padding_480_600="50px 0% 20px" item_padding_480="50px 0% 20px" item_padding="0px 5% 50px 15%"][vc_column_text el_class="destacado-blog"]Find out the main concerns related to circovirus in pigs, as for example: diagnostics, maternal antibodies interference, moment of vaccination or administration routes.

24 Oct Comparison of effects of Mhyosphere® PCV ID with three vaccine associations against Mycoplasma hyopneumoniae and PCV2 on piglet growth during nursery under field conditions

Posted at 13:29h in Intradermical route, MHYO, pcv2

The intradermal needle-free piglets started feed intake 24h earlier than the intramuscular group. Low feed intake after weaning is a factor that negatively contributes to performance during the nursery phase....

18 Oct Video: ADDRESSING M.HYO AND PCV2 VACCINATION

Posted at 11:34h in pcv2

16 Jul Effects of intradermal needle-free vaccination against Mycoplasma hyopneumoniae and Porcine circovirus type 2 on piglet performance and lung lesions at slaughter in Brazil

Posted at 07:47h in MHYO, pcv2

Mycoplasma hyopneumoniae is the causative agent of enzootic pneumonia (EP) and is one of the most prevalent and important agents associated with the porcine respiratory disease complex. EP is characterized by causing significant problems in the swine industry through endemicity, chronicity, decreased average daily gain, poor feed conversion, and increased days to market weight^1,2. Another agent associated with the porcine respiratory disease complex is Porcine Circovirus type 2 (PCV2) which is characterized by clinical or subclinical infections among pigs. The most representative symptoms of the diseases include porcine dermatitis and nephropathy syndrome, which mainly occur during the growing or finishing stages of pigs; post-weaning multisystemic wasting syndrome, which affects nursery and growing pigs; and porcine respiratory disease complex (PRDC), which usually occurs in pigs 14–20 weeks of age ^3,4. Both diseases are controlled by vaccination at weaning.

06 Jul Intradermal needle-free vaccination in piglets: effects on welfare and nursery performance

Posted at 11:08h in Intradermical route, MHYO, pcv2

A common procedure for vaccine administration for pigs has been the needle-syringe device, with intramuscular administration. However, this method is considered to be potentially painful to animals ^1,2. As a consequence of a painful vaccination process, the animals can display similar physiological alterations to a febrile response and sickness behaviours such as lethargy, decreased appetite and thirst, huddling, shivering, sleepiness, reduced groomimg and exploration, uncoordinated body movements and an increase in pain sensitivity ^3,4 resulting in a reduced production performance.

13 Oct Video: Growth performance (ESPHM 2021)

Posted at 09:28h in MHYO, pcv2

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="80px"][/vc_column][vc_column][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][qode_elements_holder number_of_columns="one_column"][qode_elements_holder_item advanced_animations="no" item_padding_480_600="50px 0% 20px" item_padding_480="50px 0% 20px" item_padding="0px 5% 50px 15%"][vc_column_text el_class="destacado-blog"]The aim of this publication was to show the effect of Mhyosphere® PCV ID vaccination in growth performance of vaccinated pigs.

intradermal vaccine against Mycoplasma hyopneumoniae

13 Oct Video: Field performance (ESPHM 2021)

Posted at 09:12h in MHYO, pcv2

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="80px"][/vc_column][vc_column][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][qode_elements_holder number_of_columns="one_column"][qode_elements_holder_item advanced_animations="no" item_padding_480_600="50px 0% 20px" item_padding_480="50px 0% 20px" item_padding="0px 5% 50px 15%"][vc_column_text el_class="destacado-blog"]In the following video, we will see the efficacy evaluation of Mhyosphere® PCV ID under field conditions, in terms of lung lesion and reduction of PCV2 viremia.

13 Oct Video: Duration of immunity (ESPHM 2021)

Posted at 08:50h in MHYO, pcv2

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="80px"][/vc_column][vc_column][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][qode_elements_holder number_of_columns="one_column"][qode_elements_holder_item advanced_animations="no" item_padding_480_600="50px 0% 20px" item_padding_480="50px 0% 20px" item_padding="0px 5% 50px 15%"][vc_column_text el_class="destacado-blog"]This publication explains the efficacy of Mhyosphere® PCV ID in terms of duration of immunity.

13 Oct Video: Onset of immunity (ESPHM 2021)

Posted at 08:13h in MHYO, pcv2

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="80px"][/vc_column][vc_column][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][qode_elements_holder number_of_columns="one_column"][qode_elements_holder_item advanced_animations="no" item_padding_480_600="50px 0% 20px" item_padding_480="50px 0% 20px" item_padding="0px 5% 50px 15%"][vc_column_text el_class="destacado-blog"]In the following video, we will see the efficacy in terms of onset of immunity of Mhyosphere® PCV ID.

10 Jun MHYOSPHERE® PCV ID (ESPHM Publications 2021)

Posted at 08:58h in MHYO, pcv2

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="80px"][/vc_column][vc_column][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][qode_elements_holder number_of_columns="one_column"][qode_elements_holder_item advanced_animations="no" item_padding_480_600="50px 0% 20px" item_padding_480="50px 0% 20px" item_padding="0px 5% 50px 15%"][vc_column_text el_class="destacado-blog"]MHYOSPHERE® PCV ID is the first and only vaccine based on a recombinant Mycoplasama hyopneumoniae (M. hyo) strain, called Nexyhon. This strain expresses the capsid proteins of Porcine Circovirus Type 2 (PCV2) in its cytoplasm and acts as the only active substance as a whole once inactivated. Furthermore, it was the first vaccine registered in Europe with demonstrated protection against all three PCV2 genotypes (a, b and d).